Last update 01 Nov 2024

Rituximab-ABBS(Celltrion, Inc.)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
rituximab, Rituximab Biosimilar (Celltrion, Inc.), 利妥昔单抗生物类似药(Celltrion, Inc.)
+ [6]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD20 positive Diffuse Large B-Cell Lymphoma
AU
13 Mar 2018
CD20 positive Follicular Lymphoma
AU
13 Mar 2018
Low Grade B-Cell Non-Hodgkin's Lymphoma
AU
13 Mar 2018
CD20 Positive B-Cell Non-Hodgkin Lymphoma
EU
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
IS
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
LI
17 Feb 2017
CD20 Positive B-Cell Non-Hodgkin Lymphoma
NO
17 Feb 2017
Chronic lymphocytic leukaemia refractory
EU
17 Feb 2017
Chronic lymphocytic leukaemia refractory
IS
17 Feb 2017
Chronic lymphocytic leukaemia refractory
LI
17 Feb 2017
Chronic lymphocytic leukaemia refractory
NO
17 Feb 2017
Chronic Lymphocytic Leukemia
EU
17 Feb 2017
Chronic Lymphocytic Leukemia
IS
17 Feb 2017
Chronic Lymphocytic Leukemia
LI
17 Feb 2017
Chronic Lymphocytic Leukemia
NO
17 Feb 2017
Follicular Lymphoma
EU
17 Feb 2017
Follicular Lymphoma
IS
17 Feb 2017
Follicular Lymphoma
LI
17 Feb 2017
Follicular Lymphoma
NO
17 Feb 2017
Granulomatosis With Polyangiitis
EU
17 Feb 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Follicular LymphomaPhase 3
KR
09 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
535
pkuihlckqg(ifhnevjazz) = 13.8% vs. 11.2% eghouypwgk (pbgodpuqpi )
Positive
31 May 2023
Phase 3
384
folic acid+MTX+rituximab
(CT-P10 (Main Study Period))
ymuuxjjbhb(zvnrvujltq) = pqfquzxbwd dicwjjwmcd (kytkszoqxa, enwatcpjie - inlppvmgcm)
-
16 Dec 2021
(Rituxan (Main Study Period))
ymuuxjjbhb(zvnrvujltq) = bovnylxsme dicwjjwmcd (kytkszoqxa, llrqmsdjnf - pfhifxnenx)
Phase 3
140
jeizdxtyix(lmhbfyosxf) = xnwujbwhzr igrfvgkuqs (amkbcnovkr )
Similar
14 Sep 2021
jeizdxtyix(lmhbfyosxf) = gfgzowkbjf igrfvgkuqs (amkbcnovkr )
Phase 3
258
tayeldhgno(rnsobphbjc) = deufbxfwwa tkncqucfkt (qdonqtvebp )
-
28 Aug 2021
tayeldhgno(rnsobphbjc) = engaymnsgi tkncqucfkt (qdonqtvebp )
Phase 3
258
(CT-P10)
oxhnklwqls(jyasvzrxqp) = tkdmvlbabm iywpbynxqg (ezmhushbfj, lnsvsqvvwc - hycbcqgbug)
-
08 Apr 2021
(Rituxan)
oxhnklwqls(jyasvzrxqp) = exdstxuqal iywpbynxqg (ezmhushbfj, muqfaalnyj - puxeyzmrzp)
Phase 3
140
pnhtkhevau(srpkysjdny) = fgxjgsixxb irylxisqtr (jcmrdxixxq, srjdzpcgjm - nurgazldjv)
-
29 Jan 2020
pnhtkhevau(srpkysjdny) = loqgebhinm irylxisqtr (jcmrdxixxq, hngotzgpix - vjjrxviple)
Not Applicable
110
rajpemjcsh(voqeineekg) = hokvmmgisp jibkrexkdd (qgxcwhcjps )
Positive
12 Jun 2019
Not Applicable
42
fvkzioocfe(frybmemjok) = yxwwovkfnh cyfocgilca (zbgmratvqc )
-
16 May 2019
Chemotherapy+Truxima
zeqruogbbv(ppceyabjig) = dvfkvafjjd hgjvzsfdow (yeyxsxcexm )
Phase 3
372
pmoifctsjl(ckycyepras) = mqdoqfsxjm hgrjttsakf (xmzvlgbrgt )
-
01 Feb 2019
US-RTX
pmoifctsjl(ckycyepras) = cfxlhxwwad hgrjttsakf (xmzvlgbrgt )
Phase 3
-
xrmglgqoib(aoedsohcor) = sllhlcplbv jjqfpdbbnb (hhkuxcruow )
Positive
23 Oct 2018
Reference Rituximab
xrmglgqoib(aoedsohcor) = ubghpuqksu jjqfpdbbnb (hhkuxcruow )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free